Agreement to Increase POC Sites in Czech Republic

Morgenesis LLC, the US point of care (POCare) services subsidiary of global cell and gene therapies developer biotech Orgenesis, has signed an agreement with contract development and manufacturing organisation SCTbio to open new POCare sites within the Czech Republic. The collaboration would leverage SCTbio’s GMP facility for the production of lentivirus vectors to support Morgenesis’ POCare worldwide customers, including use in CAR-T cell and gene therapies (CGTs).

The Orgenesis POCare Platform, including Mobile Processing Units and Labs (OMPULs), overcomes conventional processing challenges by enabling high-quality standards and sterile, scalable onsite processing of CGTs, near local hospitals and treatment facilities.

Lentiviral vectors are a fundamental component of the cell therapy manufacturing process, ensuring the delivery of the therapeutic genes into the patient’s cells. SCTbio brings expertise in retroviral vector GMP production with a deep knowledge of manufacturing technologies and quality control (QC) methods.

Ludek Sojka, Chief Executive Officer at SCTbio, stated: “We are looking forward to collaborating with Orgenesis. Its POCare Platform is a unique technology supporting the development of potentially breakthrough CGTs, and we recognise the great potential for utilising the long-term experience of our team and our GMP lentiviral vector manufacturing capabilities to support Orgenesis-powered breakthroughs in Central Europe and beyond.”

Vered Caplan, CEO of Orgenesis, commented: “This partnership reflects our commitment to helping bring potential breakthrough cell therapies to market in a cost-effective, high-quality and scalable manner. We look forward to teaming with SCTbio to expand our POCare CGT production services to the region, as well as leveraging their lentiviral vector production as a key element supporting our CAR-T customers in the EU.”

More information online